Amarante-Mendes GP - Search Results

1

Therapeutic applications of TRAIL receptor agonists in cancer and beyond.

Amarante-Mendes GP, Griffith TS. Amarante-Mendes GP, et al. Pharmacol Ther. 2015 Nov;155:117-31. doi: 10.1016/j.pharmthera.2015.09.001. Epub 2015 Sep 5. Pharmacol Ther. 2015. PMID: 26343199 Free PMC article. Review.

2

BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients.

De Carvalho DD, Binato R, Pereira WO, Leroy JM, Colassanti MD, Proto-Siqueira R, Bueno-Da-Silva AE, Zago MA, Zanichelli MA, Abdelhay E, Castro FA, Jacysyn JF, Amarante-Mendes GP. De Carvalho DD, et al. Oncogene. 2011 Jan 13;30(2):223-33. doi: 10.1038/onc.2010.409. Epub 2010 Sep 13. Oncogene. 2011. PMID: 20838376

3

Conversion of CD95 (Fas) Type II into Type I signaling by sub-lethal doses of cycloheximide.

Brumatti G, Yon M, Castro FA, Bueno-da-Silva AE, Jacysyn JF, Brunner T, Amarante-Mendes GP. Brumatti G, et al. Exp Cell Res. 2008 Feb 1;314(3):554-63. doi: 10.1016/j.yexcr.2007.11.003. Epub 2007 Nov 17. Exp Cell Res. 2008. PMID: 18078929

4

Control of death receptor ligand activity by posttranslational modifications.

Weinlich R, Brunner T, Amarante-Mendes GP. Weinlich R, et al. Cell Mol Life Sci. 2010 May;67(10):1631-42. doi: 10.1007/s00018-010-0289-7. Epub 2010 Mar 20. Cell Mol Life Sci. 2010. PMID: 20306114 Free PMC article. Review.

5

PRAME/EZH2-mediated regulation of TRAIL: a new target for cancer therapy.

De Carvalho DD, Mello BP, Pereira WO, Amarante-Mendes GP. De Carvalho DD, et al. Curr Mol Med. 2013 Feb;13(2):296-304. doi: 10.2174/156652413804810727. Curr Mol Med. 2013. PMID: 23228130 Review.

6

Improving the therapeutic potential of endostatin by fusing it with the BAX BH3 death domain.

Chura-Chambi RM, Bellini MH, Jacysyn JF, Andrade LN, Medina LP, Prieto-da-Silva AR, Amarante-Mendes GP, Morganti L. Chura-Chambi RM, et al. Cell Death Dis. 2014 Aug 14;5(8):e1371. doi: 10.1038/cddis.2014.309. Cell Death Dis. 2014. PMID: 25118931 Free PMC article.

7

BCR-ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy.

Pereira WO, De Carvalho DD, Zenteno ME, Ribeiro BF, Jacysyn JF, Sardinha LR, Zanichelli MA, Hamerschlak N, Jones GE, Pagnano KB, Castro FA, Calle Y, Amarante-Mendes GP. Pereira WO, et al. Cell Death Dis. 2017 Oct 12;8(10):e3114. doi: 10.1038/cddis.2017.458. Cell Death Dis. 2017. PMID: 29022901 Free PMC article.

8

The regulation of apoptotic cell death.

Amarante-Mendes GP, Green DR. Amarante-Mendes GP, et al. Braz J Med Biol Res. 1999 Sep;32(9):1053-61. doi: 10.1590/s0100-879x1999000900001. Braz J Med Biol Res. 1999. PMID: 10464379 Free article. Review.

9

Thymic epithelial cells mediate a Bcl-2-independent protection of single-positive thymocytes from dexamethasone-induced apoptosis.

Jacysyn JF, Conde-Moscatelli M, Barrichello CR, Silva UR, Macedo MS, Amarante-Mendes GP. Jacysyn JF, et al. Exp Cell Res. 2002 Jan 15;272(2):119-26. doi: 10.1006/excr.2001.5406. Exp Cell Res. 2002. PMID: 11777336

10

Butyrate increases apoptosis induced by different antineoplastic drugs in monocytic leukemia cells.

Ramos MG, Rabelo FL, Brumatti G, Bueno-da-Silva AE, Amarante-Mendes GP, Alvarez-Leite JI. Ramos MG, et al. Chemotherapy. 2004 Nov;50(5):221-8. doi: 10.1159/000081942. Epub 2004 Nov 3. Chemotherapy. 2004. PMID: 15528887

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

98 results

Search Page

Filters